1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,068 | 0,111 | 11.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.03. | Probiotix Health PLC - Final Results and Investor Presentation | 1 | RNS | ||
| 16.03. | Probiotix Health PLC - Notice of Results and Investor Presentation | - | RNS | ||
| PROBIOTIX HEALTH Aktie jetzt für 0€ handeln | |||||
| 17.02. | Probiotix Health PLC - PDMR Shareholding | - | RNS | ||
| 16.02. | ProBiotix says shares hit by "mistaken assumptions" of link to SkinBio | 2 | Alliance News | ||
| 16.02. | Probiotix Health PLC - Statement re Share Price Movement | 2 | RNS | ||
| 04.02. | Probiotix Health PLC - Director/PDMR Shareholding | 2 | RNS | ||
| 21.01. | ProBiotix Health says annual gross profit jumps as sales increase 45% | 3 | Alliance News | ||
| 21.01. | Probiotix Health PLC - Trading Update | 1 | RNS | ||
| 03.11.25 | Probiotix Health PLC - Move from Access to Apex Segment of Aquis | 1 | RNS | ||
| 23.10.25 | Probiotix Health PLC - Appointment of Aquis Corporate Adviser | 8 | RNS | ||
| 20.10.25 | ProBiotix partners with Wellizen on new cardiometabolic health capsule | 1 | Alliance News | ||
| 20.10.25 | Probiotix Health PLC - New Commercial Partnership in Australia | 1 | RNS | ||
| 14.10.25 | ProBiotix partners with RevivaBio on new cholesterol-lowering product | 1 | Alliance News | ||
| 14.10.25 | Probiotix Health PLC - Director/PDMR Shareholding | 1 | RNS | ||
| 14.10.25 | Probiotix Health PLC - New Commercial Partnership in Sweden | 1 | RNS |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| CO.DON | 0,014 | -20,59 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| TME PHARMA | 0,059 | 0,00 % | TME Pharma NV: TME Pharma extends financial runway to over 12 months | TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,334 | -1,18 % | Dünger-Desaster: Lieferketten-Kollaps bedroht Bayer, Nestlé, MustGrow und K+S! Wo liegt die Mega-Chance für Investoren? | Die Eskalation um den Iran hat globale Lieferketten und den Dünger- und Lebensmittelsektor in einen Ausnahmezustand versetzt, da Sanktionen und Sicherheitsrisiken den Export wichtiger Rohstoffe lahmlegen.... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,083 | +3,77 % | Replenish Nutrients Holding Corp: Replenish Nutrients appoints Glover as special adviser | ||
| GLOW LIFETECH | 0,025 | -12,50 % | Glow Lifetech Corp.: Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow | Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,012 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| NEOVACS | 0,001 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.04.2026 | Das Instrument B4A1 CH0208062627 MEIER TOBLER GRP AG NAM. EQUITY wird cum Kapitalmassnahme gehandelt am 08.04.2026 und ex Kapitalmassnahme am 09.04.2026 The instrument B4A1 CH0208062627 MEIER TOBLER... ► Artikel lesen | |
| BIOVAXYS TECHNOLOGY | 0,045 | -6,25 % | BioVaxys Technology Corp.: BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda ) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) | Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British Columbia--(Newsfile... ► Artikel lesen | |
| TELO GENOMICS | 0,037 | -6,41 % | Telo Genomics Corp.: Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman | Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,004 | -33,33 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program | MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing... ► Artikel lesen | |
| MEDMIRA | 0,030 | -28,57 % | MedMira, Inc.: MedMira Reports Second Quarter Results FY2025 | HALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2026.Corporate updateIn Q2 FY2026, the Company... ► Artikel lesen | |
| GENETIC TECHNOLOGIES | 0,034 | -100,00 % | GENETIC TECHNOLOGIES LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report Sept 2025 | ||
| BIOPHYTIS | 0,016 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.12.2025 | Das Instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM. EO -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 09.12.2025 und ex Kapitalmassnahme am 10.12.2025 The instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM.... ► Artikel lesen | |
| ACTIVE BIOTECH | 0,005 | 0,00 % | Active Biotech AB: Active Biotech Year End Report 2025 | FOURTH QUARTER IN BRIEFActive Biotech announced a fully secured rights issue, subject to approval by an extraordinary general meeting, of approximately SEK 70 million before transaction costs (October... ► Artikel lesen |
Das Unternehmen PROBIOTIX HEALTH PLC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +11,90 % bei einem Aktienkurs von 0,071 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROBIOTIX HEALTH PLC finden Sie auf Wallstreet Online.